Researchers pinpoint peptide that blocks hepatitis C virus entry

(Medical Xpress) -- Researchers at the University of Pittsburgh’s Graduate School of Public Health (GSPH) have identified a specific peptide that may block the entry of the hepatitis C virus (HCV) into the liver, representing a potential target for new drug development.

The results are available online now and will be published in the August 2012 print edition of Hepatology, the official journal of the American Association for the Study of Liver Disease.

“Viral entry is a multi-step process, involving a number of host factors; therefore, these findings represent a promising target for new antiviral drugs,” said Tianyi Wang, Ph.D., associate professor, Department of Infectious Diseases and Microbiology, GSPH, and the study’s lead author.

Previous research indicates that human apolipoprotein E (apoE), which occurs naturally in the body, forms complexes with HCV, the scientists said. They constructed peptides, dubbed hEP, containing the portions of apoE to which other proteins and lipids typically bind.

In lab tests, they found that hEP blocked the virus from binding to liver cells, preventing infection. That suggests apoE is involved with HCV’s initial entry into the cells, Dr. Wang said. It’s possible that hEP thwarts infection because it competes with HCV for a cell surface receptor.

In addition, researchers determined that the ability of hEP to block the virus appears to be dependent on the peptide’s length and sequence. Shorter versions could not stop infection, possibly because the shape of the proteins—and thus their binding ability—was altered.

“Our findings highlight the potential of developing peptides that mimic hEP as new viral inhibitors,” said Dr. Wang.

Worldwide, more than 170 million people are infected with the hepatitis C virus, which often is asymptomatic and can cause severe liver disease and liver cancer. There is no cure for HCV and no vaccine. Existing treatments are effective in only 40 percent to 80 percent of patients and can cause severe side effects.

Despite the recent U.S. Food and Drug Administration approval of two new antiviral drugs designed to treat chronic HCV infection, patients may rapidly develop resistance. Much like current HIV therapies, successful treatment of HCV may involve multiple inhibitors of different targets, researchers said.

“New antiviral drugs are urgently needed to treat HCV infection independently, or in combination with current therapies,” said Dr. Wang.

Collaborators on the studies include Shufeng Liu, Ph.D., and Kevin D. McCormick, M.S., Department of Infectious Diseases and Microbiology, GSPH, University of Pittsburgh; Wentao Zhao, Ph.D., and Daping Fan, Ph.D., Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina; and Ting Zhao, Department of Pathology, University of Pittsburgh School of Medicine.

Related Stories

New vaccine for hepatitis C virus

Jul 28, 2011

Murdoch University researchers have begun a study to develop a new and innovative vaccine for the hepatitis C virus (HCV).

Improved culture system for hepatitis C virus infection

Jul 16, 2008

A University of California, San Diego School of Medicine researcher has developed the first tissue culture of normal, human liver cells that can model infection with the Hepatitis C virus (HCV) and provide a realistic environment ...

Recommended for you

Recorded Ebola deaths top 7,000

4 hours ago

The worst Ebola outbreak on record has now killed more than 7,000 people, with many of the latest deaths reported in Sierra Leone, the World Health Organization said as United Nations Secretary-General Ban ...

Liberia holds Senate vote amid Ebola fears (Update)

8 hours ago

Health workers manned polling stations across Liberia on Saturday as voters cast their ballots in a twice-delayed Senate election that has been criticized for its potential to spread the deadly Ebola disease.

Evidence-based recs issued for systemic care in psoriasis

Dec 19, 2014

(HealthDay)—For appropriately selected patients with psoriasis, combining biologics with other systemic treatments, including phototherapy, oral medications, or other biologic, may result in greater efficacy ...

Bacteria in caramel apples kills at least four in US

Dec 19, 2014

A listeria outbreak believed to originate from commercially packaged caramel apples has killed at least four people in the United States and sickened 28 people since November, officials said Friday.

Steroid-based treatment may answer needs of pediatric EoE patients

Dec 19, 2014

A new formulation of oral budesonide suspension, a steroid-based treatment, is safe and effective in treating pediatric patients with eosinophilic esophagitis (EoE), according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.